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Abstract 
There is a long history of women being under-represented in biomedical and health research. 
Specific women’s health needs have been, and in some cases still are, comparatively neglected areas 
of study. Concerns about the health and social impacts of such bias and exclusion have resulted in 
inclusion policies from governments, research funders, and the scientific establishment since the 
1990s. Contemporary understandings of foregrounding sex and gender issues within biomedical 
research range from women’s rights to inclusion, to links between human rights, women’s health 
and sustainable development, and the increasing scientific and funding expectation for studies to 
consider the sex (biological) and gender (cultural) implications of research design, results and 
impact. However, there are also exploitation issues to consider when foregrounding the inclusion of 
women as research participants, especially for research ethics committees and institutional review 
boards. A hidden risk is that exploitative research designs and practices may be missed, particularly 
by reviewers who may not have a nuanced understanding of gender-based harm. Utilising 
contemporary case studies of ethics dumping, this paper highlights some of the concerns, and makes 
recommendations for IRBs/research ethics reviewers to help ensure that essential research is 
undertaken to the highest ethical standards.  
 
Introduction 
Since the 1960s there has been an increasing focus on the inclusion of women’s health needs in 
research.1 
There is a long history of women being under-represented in biomedical and health research. 
Specific women’s health needs have been, and in some cases still are, comparatively neglected areas 
of study (e.g. endometriosis2). But until the late 20th century researchers often excluded women 
from clinical trials on the simultaneous (if conflicting) bases that women would have the same 
responses to drugs as men,3 and that women were confounding subjects because of fluctuating 
hormone levels.4  
It is now well-understood that sex differences are an important variable in health, from the genetic 
or cellular to the organismal and behavioural levels, and that sex differences are observable in 
various disease states. For example, incidence, signs and symptoms of lung cancer, cardiovascular 
disease and sexually transmitted infections (STIs) can affect women differently from men. Outcomes 
and responses to treatment also vary by sex, and physiology can translate into differences in 
pharmacokinetics and pharmacodynamics for specific drugs.5 Scientifically, sex is generally 
understood as classification by chromosomal complements, with gender seen as a cultural 
dimension of sex expression and response.6 Health inequalities due to such gendered cultural and 
social factors are also well-recognised.7 
Concerns about the health and social impacts of such bias and exclusion in research have resulted in 
inclusion policies from governments, research funders, and the scientific establishment since the 
1990s.8 The Gendered Innovations in Science, Medicine and Health, and Engineering and 
Environment Project, through Stanford University, the European Commission and the U.S. National 
Science Foundation, identifies three strategic approaches to gender equality over the past several 
decades: 
1. "Fix the Numbers of Women" focuses on increasing women's participation. 
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2. "Fix the Institutions" promotes gender equality in careers through structural change in 
research organizations. 
3. "Fix the Knowledge" or "gendered innovations" or the "gender dimension" stimulates 
excellence in science and technology by integrating sex and gender analysis into research.9 
This strategy has formed the focus of debates and policies, as well as the literature about the 
necessity to include women and women’s needs in biological and health research. These 
developments have been supported by the intersection of two global movements. The first is the 
movement to address gender inequality. At an international policy level this has been largely driven 
by the continued implementation of the Platform for Action that emerged from the 1995 United 
Nations (UN) Development Programme Fourth World Conference on Women, in Beijing,10 “which 
remains the most comprehensive document of the world’s commitment to women’s rights”.11 In 
2010, UN Women was established as a single recognized driver to work for the elimination of 
discrimination against women and girls, empowerment of women, and achievement of equality 
between women and men as partners and beneficiaries of development, human rights, 
humanitarian action and peace and security.12  
The second movement is the need to achieve sustainable development, initiated globally through 
the Convention on Biological Diversity13 at the 1992 Rio Earth Summit, and also addressed through 
the UN Millennium Development Goals (2000 – 2015), and the 2016-30 Sustainable Development 
Goals (SDGs, also known as Agenda 30). These two movements have become increasingly entwined, 
from grass roots activism through to national and international agendas,14 such that it is now 
recognised at the highest global level, as well as by many citizens worldwide, that sustainable 
development cannot be achieved without the full empowerment of women and girls (SDG 515).  
Contemporary understandings of foregrounding sex and gender issues within biomedical research 
therefore range from women’s rights to inclusion in research studies,16 to the links between human 
rights,17 women’s health18 and sustainable development,19 and the increasing scientific and funding 
expectation for studies to consider the sex (biological) and gender (cultural) implications of research 
design, results and impact20,21,22. However, there are also gender exploitation issues to consider 
when women are included in research. For example, Carly Drake and Jacqueline Gahagan argue that 
using women as health promotion change agents in HIV interventions aimed at men creates burdens 
for women without benefits, and reinforces gender stereotypes which are differentially harmful to 
both the women, and the men concerned.23 
In recent years the need to achieve equity in international research has become a pressing concern. 
The term ‘ethics dumping’ was first used by the European Commission to characterise research 
carried out by institutions from high income countries (HICs) in low or middle-income countries 
(LMICs) in a way which would not be accepted in the home settings (e.g. Europe or USA).24 
“Ethics dumping” occurs mainly in two areas. First, when research participants 
and/or resources in low- and middle-income countries (LMICs) are exploited 
intentionally, for instance because research can be undertaken in an LMIC that 
would be prohibited in a high-income country. Second, exploitation can occur due to 
insufficient ethics awareness on the part of the researcher, or low research 
governance capacity in the host nation.25  
Questions about how to counter these unethical research practices have become the subject of 
international attention, building on existing guidelines such as the Declaration of Helsinki26 and the 
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Council for International Organizations of Medical Sciences CIOMS Guidelines27 to produce new 
recommendations for good practice.28 
A 2018 book, Ethics Dumping: Case Studies from North-South Research Collaborations,29 provides 
evidence of ethics dumping across six themes in international research; vulnerable populations, 
clinical trials, benefit sharing, animal research, new and emerging technologies (NEST), and ethical 
and governance processes. Ethics Dumping does not explicitly apply a gender perspective to its 
themed analysis of risks for ethics dumping, but in this paper I utilise two cases from the anthology 
to discuss gender issues raised by studies which only include female research participants. 
I argue that a hidden risk of foregrounding the inclusion of women as research participants is that 
exploitative research designs and practices may be missed, particularly by ethics reviewers who may 
not have a nuanced understanding of gender-based harm. Enriching our understanding of the 
patterns which underlie ethics dumping can support more robust ethics review of research, and 
protect female research participants from exploitation, in a world where as a result of progressive 
policies they are more likely than ever to be recruited as participants in biomedical research.  
 
Human Food Trial of a Transgenic Fruit 
This case study30 discusses the controversial proposed trial of a transgenic fruit in North American 
university students, who would be paid to eat a strain of genetically altered bananas destined for 
use in a LMIC (Uganda). It locates the risks to potential participants in the context of tensions 
between the concepts of food security31 and food sovereignty,32 and makes recommendations 
regarding ethics in agricultural research and the requirement to match research to local (i.e. 
proposed destination) needs. However, although the case study raises the specific risks of unknown 
human health impacts to female participants of childbearing age, it does not ask why only female 
students were invited to take part in the trial in the first place. This gap is also evident in public 
communications from ‘AGRA watch’, a grassroots, Seattle-based group challenging the Bill and 
Melinda Gates Foundation’s (BMGF) agricultural programs in Africa, who organised a petition against 
the study in 2016.  A quote provided in the ‘AGRA watch’ literature from a molecular biologist based 
at the Salk Institute that “...a feeding trial in people, especially women, should not be allowed.”, 
largely passes without further comment.33 
Initial local press reports on the controversy noted that the invitation was to female students, yet 
only discussed opponents’ concerns in terms of generic risks to human health. The case study 
reports that the lead researcher publicly stated in her ‘defence’ that she had previously led a study 
with women eating food modified to contain high levels of beta-carotene. However, the published 
results of that original study also provide no justification for including only women as participants, 
and further, the original study discusses and compares the results only in terms of “healthy adults”.34 
Interestingly, journalists comment in a report on the banana study that, “It's not clear why they had 
to be female, but our guess is that pregnant or nursing women and their children are especially 
vulnerable [to] vitamin A deficiency”.35 Maybe bioethicists and research ethics reviewers should be 
concerned that this basic question about the design of the study seems only to have been addressed 
by the “guesses” of journalists. 
More recent local press coverage of the controversy has dropped any references to the gender of 
the student participants at all.36 So it seems that specific concerns about the inclusion of women in 
the trial have been increasingly backgrounded in favour of discussion about risks to humans in 
general, when in fact the risks here were only to women. One might think this a strategic 
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campaigning failure by those opposed to the trial, but of greater concern is the lack of bioethical 
attention to this not insignificant detail. 
A clue lies in the suggestion by the journalists quoted above. The ‘banana 21’ project37 was initiated 
by Queensland University of Technology in Australia with funding from BMGF. The project website 
and statements from the US university conducting the trial all rightly stress the global public health 
burden of vitamin A deficiency in babies and pre-school children, which is most prevalent in Africa 
and South East Asia. The World Health Organization (WHO) describes the health burden for pregnant 
women globally in high risk areas.38 So there are undoubtedly important bioethical questions to be 
asked about who would benefit most from successful solutions to address this problem, which 
seems to occur predominantly in LMICs. However, there seems to be a conceptual jump between 
global maternal and child health and mortality concerns, and the automatic and largely 
unquestioned inclusion of healthy women in a HIC as ideal testing grounds for the transgenic 
bananas.  
This potentially raises an interesting reversal of the traditional bioethical critique of the use of 
populations in LMICs to test innovations that will predominantly benefit HIC populations.39 However, 
I am not arguing here that these tests should take place in a different international setting with more 
vulnerable participants, although there may well be arguments for conducting the trials in the 
country the fruit is intended for. Here, I would like to explore the conceptual shift that assumes the 
female American students were appropriate participants for this study, asking how this lack of 
gender awareness impacts on the design and ethical approval of research studies. 
Leaving aside issues of how well the participants were informed about the proposed study and the 
quality of their consent, it is important to recall that students in an institution are by definition 
potentially vulnerable participants due to their hierarchical/subordinate relationship with 
researchers at that (or other) institutions.40 Therefore there are questions here about whether this 
research could have been more widely conducted in the general population, or if it was targeted at 
students, as is still so often the case, for ease of recruitment.41,42 
A USD$900 fee was offered for participation, so in a student population which is (relatively) 
impoverished compared to the general population, there are potential issues of inducement here, 
again denoting vulnerability. It is well-documented that in any setting globally, there is a gender 
wealth gap, and in the USA today, “Based on median annual earnings, a woman working full time, 
year-round typically earns only 79 cents for every dollar earned by her male counterpart. The 21-
percent difference in earnings (or 21 cents on the dollar) is known as the “gender pay gap”.43 This 
means that any financial inducement is likely to be more of an inducement for a woman than a man, 
even in a HIC. This problem does not disappear if only women are to be recruited; instead it leaves 
us with a situation where all of the potential participants are at risk of inducement. 
Attention to these questions at ethics review might have headed off some of the resulting high-
profile controversy, so there are pragmatic concerns here too, specifically in the context of the 
institutional protection role of Institutional Review Boards (IRBs) in the US. 
Raising a general concern about the exploitation of women in research may initially seem misplaced 
regarding this small study in a HIC. However, the overall ‘banana 21’ project to release genetically 
modified foods into an LMIC has enormous implications. The controversial transgenic banana trial 
was not a traditional clinical trial, yet given the gender issues it raises, one might propose that ethics 
review processes should ask more questions about gender variety/balance in research participation 
and how this impacts on risk/benefit assessments. 
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Cervical Cancer Screening In India 
A second case study in Ethics Dumping describes three linked cluster-randomized clinical trials that 
took place in India between 1998 and 2015 to determine whether trained health workers could 
conduct cervical cancer screening using cheaper visual methods of screening than cytology (Pap 
smear) to reduce the incidence and mortality of cervical cancer.44 Approximately 374,000 poor and 
socially disadvantaged women were included, with 141,000 of them allocated to a control group of 
no screening; in two of the trials they simply received one-off health education on the causes of 
cervical cancer, and information about available services, in the third there was no control group 
intervention, and outcomes of incidence or mortality of cervical cancer were subsequently collected 
through data monitoring. The trials are enormously controversial as known and effective methods of 
screening (Pap smear) were withheld from the high-risk control group, despite being available in all 
major hospitals, and having been recognised as the standard of care in India since the 1970s. 
However, due to the lack of universal availability of Pap smear under a government programme, the 
trials (mis)construed the existing standard of care for the control group as no screening (no active 
care). To date 254 women in the control arm are known to have died due to undetected and 
untreated cervical cancer. 
This is a classic and tragic story of ethics dumping, which demonstrates the harm caused to 
participants in LMICs by research designs that would not be permitted in the country of the funders, 
in this case the USA (BMGF and National Institutes of Health (NIH)), and France (International 
Agency for Research on Cancer (IARC)). The case study authors argue that a catalogue of scientific 
and regulatory weaknesses and structural and economic inequities combined to lead to the violation 
of a range of rights for the control group participants, including the right of access to the highest 
available standard of healthcare, and the universal right to life. 
In this case study, it is self-evident that the subject of the study is global women’s health needs, and 
that all the participants were necessarily women. Therefore a gender analysis might at first glance 
seem superfluous. Indeed the researchers’ defences of their methodology have relied on this claim 
to justify their work. Who would not support investigation into more accessible methods of cervical 
cancer screening for vulnerable women in LMICs which struggle to provide universal access to the 
acknowledged standard of care? However, if we take a step back this case raises crucial issues about 
women’s participation in such studies, with strong echoes of the ethics debates over maternal-fetal 
transmission of HIV trials in the 1990s.45,46 
The participants in the cervical cancer trials were poor, uneducated women at risk of increased 
mortality and morbidity from a range of preventable health conditions, without universal access to 
healthcare, and so were vulnerable.47 But this vulnerability is due to pre-existing structural 
inequalities, and it is widely recognised in the international sustainable development agenda that 
these have a powerful gender dimension. For example, the UN Committee on the Elimination of 
Discrimination against Women states: 
Globally, and with few exceptions, rural women disproportionately experience 
poverty and exclusion. They face systemic discrimination in accessing land and 
natural resources. Even when formally employed, they are more often engaged in 
work that is insecure, hazardous, poorly paid and not covered by social protection. 
They are less likely to be educated and are at higher risk of being trafficked and 
forced into labour, as well as into child and/or forced marriage and other harmful 
practices.48 
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The impact of gender on vulnerability 
Building on Doris Schroeder and Eugenijus Gefenas’ definition of vulnerability,49 I have previously 
argued that issues of gendered vulnerability in research can be defined as the probability of 
incurring harm while lacking protection mechanisms due to gendered inequalities: 
There is a need for a nuanced, contextualised understanding of gender-based 
vulnerability among population groups as a basis for developing responses that give 
special protection to the most vulnerable. If the poor are at the bottom of the social 
ladder, poor women are on the lowest rung.50 
The above two case studies show contrasting settings in which women are rendered differentially 
vulnerable to exploitation in research due to pre-existing and structural gender-based inequalities. 
This reveals that there is a need to address the wider gender issues raised by the context of specific 
research studies,51 which in turn requires sensitivity to the gendered dimension of the vulnerability 
of research participants of all types (direct, controls etc.). 
Ethics guidelines and the practical work of research ethics committees constantly require us to 
consider differentials amongst participants when evaluating a study proposal. But a homogenous 
participant group can mask such differentials. 
Where research takes place in a context of persistent and systematic gender inequality, all-women 
participant groups can obscure the ways in which research itself can exploit, contribute to and even 
exacerbate those inequalities.52 It is easy to miss the ‘red flags’.  But consciously applying a gender 
lens can facilitate this process, and help us to step back and ask - if the participants are all women, 
then where will we find the gender-based vulnerabilities that may lead to ethical problems? This can 
help us to resist, for example, the leveraging of genuine health needs (in both cases here, of poor 
LMIC women) to mask the exploitation of female research participants.  
In the case of the ‘banana 21’ trial, such an approach might have challenged the study design and 
avoided a controversy. In the cervical cancer trials, although it is obvious why only women would be 
recruited to such studies, that the participants are all women still works as an indicator (‘red flag’) 
for their potential vulnerability to exploitation; and this enables us to ask searching questions about 
a trial where there is not only no possible benefit to the control group, but a potential for actual 
harm, including loss of life. 
Analysing and connecting themes of gender inequality in case studies, such as the two discussed in 
this paper, can therefore support researchers and bioethicists to ask wider and deeper questions 
about gender justice in research. 
Conclusion and Recommendations 
The worldwide movement towards identification of and investment in women’s health needs and 
the inclusion of women as participants in biomedical research should not ignore continuing issues of 
exploitation. In the 1990s, bioethical debates about maternal-fetal HIV transmission studies were 
“embedded in the far broader debate on the conditions under which research in Third World nations 
should take place”.53 We now live in a time where ethics dumping in international research has 
become a paramount concern. So perhaps it is time that discussions about the gendered ethical 
issues raised by these case studies also became embedded in this broader debate on the conditions 
under which research on women only should take place. 
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IRBs/reviewers should: 
• Note single gender cohorts as a ‘red flag’: 
There should be an expectation that researchers will include a justification for single 
gender cohorts in their application for ethics approval. 
• Feel confident to ask questions or challenge the appropriateness of a single gender research 
design: what research purpose does this serve, and what benefits could it have for this 
gender? 
 
• Relate ethics approval for single gender cohorts to the mitigation of risks in the research 
context: 
Taking gender inequity as a starting point, in what ways are this participant group 
vulnerable in their community or society - how might participation in the proposed 
study exploit those conditions, or exacerbate them? 
IRB/ethics review should (where appropriate) consider opinions or input from 
local/host ethics committees, and patient and public involvement in research design, 
including advocates/representatives, to help assess and mitigate potential gender-
based harms for research participants. 
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